Monthly Archives: June 2020

Ample Market Research has recently published a report Human Embryonic Stem Cells Market . The key objective of this report is to highlight various trends and dynamics, new and innovative technology and mergers and acquisitions that are expected to make a positive impact on the overall industry. This report studies the Human Embryonic Stem Cells market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report provides a detailed analysis of the prospects for the global Human Embryonic Stem Cells industry up to 2024, including an assessment of the impact of COVID-19.

To know How COVID-19 Pandemic Will Impact This Market/Industry -Request a sample copy of the report: https://www.amplemarketreports.com/sample-request/global-human-embryonic-stem-cells-market-1731516.html

Human Embryonic Stem Cells Market Latest Research Report 2018- 2025 covers a complete market structure across the world with a detailed industry analysis of major key factors. This report provides strategic recommendations consulted by the industrial experts including market forecasts, profit, supply, raw materials, manufacturing expenses, the proportion of manufacturing cost structure, latest market trends, demands and much more.

Global Human Embryonic Stem Cells Market is valued approximately USD XX billion in 2019 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2020-2026. Due to COVID-19 pandemic, the market is facing challenges because of government protocols to stay at home across the world. Human Embryonic Stem Cells (hESCs) are derived from blastocyst and are capable of differentiating into number of cell types that make up the human body as well as it replicates indefinitely and produce non-regenerative tissues such as neural and myocardial cells. They are used in treating a number of blood and genetic disorders related to the immune system, cancers, and disorders as well as used in investigational studies of early human development, genetic diseases and toxicology testing. The technological advancement involving stem cells therapy, rising demand for regenerative medicines, R&D in toxicology testing, technological advancements for the production of embryonic stem cells through alternative methods and increasing prevalence of genetic disorders are the few factors responsible for growth of the market over the forecast period. Furthermore, the introduction of innovative products and other strategic advancements by market players will create lucrative opportunities for the market. For instance, as per companys news release in January 2019, Stemcell Technologies Inc. launched mTeSRl Plus, an enhanced version of mTeSR1. mTeSR Plus is the stabilized feeder-free maintenance medium for human embryonic stem (ES) and induced pluripotent stem (iPS) cells. However, ethical concern related to stem cell research is the major factor restraining the growth of global Vegetable Chips market during the forecast period.

The regional analysis of global Human Embryonic Stem Cells market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. Asia Pacific is the leading/significant region across the world due to the presence of several prominent entities incorporated in the U.S. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2026.

This report discusses the key drivers influencing Human Embryonic Stem Cells market growth, demand, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on current and future development.

Human Embryonic Stem Cells market report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.

Key players analyzed in the Human Embryonic Stem Cells Insight Report: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell Technologies Inc., Biotime, Inc. / Cell Cure Neurosciences LTD, Thermo Fisher Scientific, Inc., CellGenix GmbH, ESI BIO, PromoCell GmbH, Lonza Group AG, Kite Pharma, Cynata Therapeutics Ltd.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Browse Detailed TOC, Tables, Figures, Charts And Companies Mentioned In Human Embryonic Stem Cells Market Research Report At: https://www.amplemarketreports.com/report/global-human-embryonic-stem-cells-market-1731516.html

Strategic Points Covered in Table of Contents

Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global Conductive Nylon market, years considered, and study objectives. Additionally, it touches the segmentation study provided in the report on the basis of the type of product and application.

Executive Summary: It gives a summary of key studies, viz. production, market growth rate, competitive landscape, market drivers, trends, and issues, and macroscopic indicators.

Production by Region: Here, the report provides information related to import and export, revenue, production, and key players of all regional markets studied.

Profile of Manufacturers: Each player profiled in this section is studied on the basis of SWOT analysis, their products, production, value, capacity, and other vital factors.

Market Size by Manufacturer

Consumption by Region

Market Size by Type,by Application

Production Forecast and Consumption Forecast

Industry Chain, Upstream, and Downstream Customers Analysis

Key Findings, Opportunities and Challenges, Threats, and Affecting Factors

Appendix

Get Complete Report in your Inbox within 24 hours Now at : https://www.amplemarketreports.com/buy-report.html?report=1731516&format=1

In the end, this report additionally presents product specification, producing method, and product cost structure. Production is separated by regions, technology, and applications. The Human Embryonic Stem Cells Market report includes investment come analysis and development trend analysis. The key rising opportunities of the fastest growing international Human Embryonic Stem Cells industry segments are coated throughout this report. This report provides information about the import, export, consumption and consumption value. The report then provides one of the most crucial aspects of the Human Embryonic Stem Cells Market the forecast for the next five to six years based on the previous as well as current data.

About Ample Market Research

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Attention to detail, consistency, and quality are elements we focus on. However, our mainstay remains to be knowledge, expertise, and resources to make us industry players.

Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Us

Ample Market Research & Consulting Private Limited

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: [emailprotected]

Website: http://www.amplemarketreports.com

View post:
Excellent growth of Human Embryonic Stem Cells Market- Comprehensive study by key players: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell...

SAN FRANCISCO, June 3, 2020 /PRNewswire/ --The global cell expansion marketsize is expected to reach USD 39.7 billion by 2027 registering a CAGR of 9.4%, according to a new report by Grand View Research, Inc. Cell expansion techniques are increasingly employed for the development of cellular and gene therapies from a single cord blood collection. These techniques can also be used for the expansion of stored Stem Cells (SCs) for the development of cancer therapies. Therefore, significant developments in cord blood SCs expansion technologies are expected to boost market growth.

Key suggestions from the report:

Read 170 page research report with ToC on "Cell Expansion Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables), By Cell Type (Mammalian, Animal), By Application, By End Use, And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/cell-expansion-market

Companies have made heavy investments for the expansion of tissue-engineered products and the development of biologics. For instance, in March 2019, Merck KGaA invested USD 168 million for the expansion of its biologics manufacturing facility in Switzerland. Such initiatives are expected to boost the demand for solutions required for biologic development, thereby leading to market growth.

Bioreactors are fundamental tools in this market. Extensive research studies related to the applications of bioreactor engineering approaches have led to the incorporation of novel culture technologies. Moreover, the combined use of automated bioreactors with the microcarrier technology leads to an efficient expansion and enrichment of the cancer SCs. As a result, these approaches have gained immense traction in this market.

Grand View Research has segmented the global cell expansion market on the basis of product, cell type, application, end use, and region:

Find more research reports on Biotechnology Industry, by Grand View Research:

Gain access to Grand View Compass,our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: 1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected] Web: https://www.grandviewresearch.com Follow Us: LinkedIn | Twitter

SOURCE Grand View Research, Inc.

See the original post:
Cell Expansion Market Worth $39.7 Billion by 2027 l CAGR 9.4%: Grand View Research, Inc. - PRNewswire

At the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, speaker Leslie R. Ellis, MD, MSHPEd, FACP, associate professor of medicine, Wake Forest Baptist Health, Comprehensive Cancer Center Winston-Salem, discussed the results of studies in a session looking into current research on leukemia, myelodysplastic syndromes (MDS), and allotransplant.1

Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax

The first study discussed was the phase 1b/2 trial looking into the adverse effects and dosing of venetoclax when paired with ivosidenib, with or without being paired with azacitidine additionally. These treatments were used with participants in the study who had IDH1-mutated hematologic malignancies.1,2

The results demonstrated that venetoclax and ivosidenib may stop cancer cell growth by blocking some of the enzymes necessary for cell growth. In chemotherapy, drugs such as azacytidine work differently by hindering growth of cancer cells through either killing the cells, stopping them from dividing, or stopping them from spreading.1,2

The researchers found that treatment with ivosidenib and venetoclax with azacitidine may be more effective when treating patients with IDH1-mutated AML, compared with ivosidenib and venetoclax alone. Ellis added that the results demonstrated that further follow up and accrual would be ongoing in order to better define the duration and biomarkers of response in patients.1,2

OPTIC Study of Ponatinib for Chronic Phase-CML

The second study discussed in the session was the phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial evaluating response-based dosing regimens of ponatinib over a range of 3 starting doses (45 mg, 30 mg, 15 mg).1,3

The aim of the study was to optimize the treatments efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who were found to be resistant or intolerant to tyrosine kinase inhibitor therapy.1,3

With median follow-up time of approximately 21 months, data from the interim analysis demonstrated that the optimal benefit-risk profile for ponatinib in patients with CP-CML was observed at a daily starting dose of 45 mg followed by a reduction to 15 mg after achieving 1% BCR-ABL1. Following this dose reduction to 15 mg/day, the optimal benefit to treatment was demonstrated to be maintained by patients. This dosing regimen was also found to result in an adjudicated arterial occlusive event rate of 5.3%.1,3

Ellis explained that the complete primary analysis of the trial will occur after all patients are able to have at least 12 months of follow-up, with the resulting data being presented following this occurrence.1,3

Pediatric Disease Risk Index for Allogeneic Stem Cell Transplantation

In the final study discussed during the session, Ellis presented a recently developed validated pediatric disease risk index (p-DRI) for acute myeloid (AML) and acute lymphoblastic leukemia (ALL) that provides a stratification of children receiving allogeneic hematopoietic cell transplantation for prognostication.1,4

Characteristics such as disease, disease status, and cytogenetic abnormalities are known to effect relapse and survival in patients following transplantation for AML and ALL. It has previously been observed in adults that these attributes can be used to develop a disease risk index for survival. For this reason, the analysis conducted was aimed to develop and validate a p-DRI.1,4

Patients who were younger than 18 years with AML and ALL transplanted between 2008 and 2017 in the United States were eligible for the p-DRI, with separate analyses performed for both AML and ALL. Each patient was randomly assigned to a training and validation cohort.1,4

In order to select significant variables, the researchers used the Cox proportional hazards model with stepwise selection. The primary outcome was leukemia-free survival (LFS).1,4

There were 4 risk groups identified for AML and 3 risk groups for ALL. The probabilities over 5 years of LFS for AML were 81%, 56%, 44%, and 21% for good, intermediate, high, and very high-risk groups, respectively. For ALL, the probabilities over 5 years of LFS for ALL were 68%, 50%, and 15% for good, intermediate, high risk groups, respectively.1,4

Ellis explained that based on these results, the researchers were able to validate that the p-DRI effectively stratified children with AML and ALL for prognostication undergoing allogeneic transplantation.1,4

REFERENCES

Original post:
Highlights of Current Research on Leukemia, MDS, and Allotransplant - Pharmacy Times

WASHINGTON, June 3, 2020 /PRNewswire/ --A new systematic review and meta-analysis of clinical studies using mesenchymal stromal cells (MSCs) led by a team at the Mayo Clinic, and including researchers from Emory, Duke, Case-Western, and the University of Miami, shows a trend toward improved outcomes and reduced mortality for patients with acute respiratory distress syndrome (ARDS), a major complication for patients with COVID-19. This studyand several othersalso have shown that MSCs are safe for patients.

Based on these findings, the authors call for the rapid commencement of large-scale, confirmatory clinical trials to build on the existing evidence base, which shows a trend toward improved pulmonary function and reduced severe lung inflammation for patients with ARDS, paving the way toward another treatment option for seriously ill patients with COVID-19.

To date, nearly two million Americans have tested positive for COVID-19 and more than 100,000 Americans have died. In its most severe form, COVID-19 leads to ARDSa life-threatening lung injury that allows fluid to leak into the lungs and makes it difficult for patients to breathe. More than 40 percent of individuals hospitalized for severe and critical COVID-19 develop ARDS, and 22 percent to 62 percent of those who are diagnosed and become critically ill, die from the disease. There is no effective treatment for ARDS today; MSCs potentially offer a unique therapeutic option to help patients in need.

"The analysis shows a positive trend in outcomes when treating ARDS patients with MSC therapy and represents the potential to save thousands of patients with COVID-19 induced ARDS," said Wenchun Qu, MD, PhD of the Mayo Clinic and first author of the paper. "The potential benefitcombined with the demonstrated safety of these therapiessupports the need for rapid commencement of more clinical trials."

"Acute respiratory distress syndrome is a rapidly progressive disease that can occur in critically ill patients," said Anthony Atala, MD, Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "Having additional potential therapies, such as MSCs, could be highly beneficial to patients with COVID-19."

To date, the FDA has approved more than a dozen investigational new drug applications for the use of MSCs for COVID-19-related conditions. The National Institutes of Health (NIH) has also supported the use of MSCs and other regenerative cell therapies to help patients with other conditions. The bipartisan 21st Century Cures Act provided $30 million in funding to the NIH over three years for clinical research for such therapies. However, these limited investments expire in fiscal year 2020.

The Alliance for Cell Therapy Now and the Regenerative Medicine Foundation support the recommendation of the authors, who urge funding for larger studies that build on the results to date. Collaboration and funding are also needed to collect and analyze the evidence from multiple ongoing and new studies, to better evaluate outcomes and potential benefits of MSC therapy for COVID-19 patients in need. A portion of the more than $10 billion in funding directed by Congress to the Biomedical Advanced Research and Development Authority (BARDA) and the NIH for COVID-19 should be used to support these goals.

About the Alliance for Cell Therapy Now

Alliance for Cell Therapy Now (ACT Now) is an independent, non-profit organization devoted to advancing the availability of and access to safe and effective cell therapies for patients in need. ACT Now convenes experts and stakeholders to develop and advance sound policies that will improve the development, manufacturing, delivery, and improvement of regenerative cell therapies. See http://allianceforcelltherapynow.org/

About the Regenerative Medicine Foundation

The non-profit Regenerative Medicine Foundation (RMF) fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honoring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives. STEM CELLS Translational Medicine is RMF's official journal partner. See https://www.regmedfoundation.org/

View original content:http://www.prnewswire.com/news-releases/msc-therapy-for-acute-respiratory-distress-syndrome-its-time-to-accelerate-clinical-trials-for-covid-19-patients-in-need-301070329.html

SOURCE Alliance for Cell Therapy Now

Go here to see the original:
MSC Therapy for Acute Respiratory Distress Syndrome; It's Time to Accelerate Clinical Trials for COVID-19 Patients in Need - P&T Community

The latest report pertaining to Stem Cell Characterization and Analysis Tool Market now available with Market Study Report, LLC, provides a detailed analysis regarding market size, revenue estimations and growth rate of the industry. In addition, the report illustrates the major obstacles and newest growth strategies adopted by leading manufacturers who are a part of the competitive landscape of this market.

.

Request a sample Report of Stem Cell Characterization and Analysis Tool Market at:https://www.marketstudyreport.com/request-a-sample/2679261?utm_source=bulletinline&utm_medium=ADS

The latest report on the Stem Cell Characterization and Analysis Tool market contains a detailed analysis of this marketplace and entails information about various industry segmentations. According to the report, the market is presumed to amass substantial revenue by the end of the forecast duration while expanding at decent growth rate.

Details regarding the industry size, remuneration potential, and volume share are compiled in the report. It further lists out the drivers and challenges that will impact the growth of Stem Cell Characterization and Analysis Tool market during the estimated timeframe.

The Stem Cell Characterization and Analysis Tool market with respect to the geographical terrain:

Ask for Discount on Stem Cell Characterization and Analysis Tool Market Report at:https://www.marketstudyreport.com/check-for-discount/2679261?utm_source=bulletinline&utm_medium=ADS

Additional highlights from the Stem Cell Characterization and Analysis Tool market share report are enlisted below:

Table of Contents:

Executive Summary: It includes key trends of the Stem Cell Characterization and Analysis Tool market share related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Stem Cell Characterization and Analysis Tool market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Stem Cell Characterization and Analysis Tool market.

Market Segments: This part of the report discusses about product type and application segments of the Stem Cell Characterization and Analysis Tool market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

For More Details On this Report:https://www.marketstudyreport.com/reports/global-stem-cell-characterization-and-analysis-tool-market-2020-by-company-regions-type-and-application-forecast-to-2025

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Stem Cell Characterization and Analysis Tool Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Stem Cell Characterization and Analysis Tool Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Related Reports:

1. Global Sterile Vial Adaptor Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025The Sterile Vial Adaptor Market Report offer the complete scenario of the industry and valuation of upcoming Trends for future market. It also gives the analytic of enduring growth factor, trends and statistic of Sterile Vial Adaptor Market industry. The Sterile Vial Adaptor Market has been outlined by overall information and analysis.Read More: https://www.marketstudyreport.com/reports/global-sterile-vial-adaptor-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Protective Medical Gowns Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Protective Medical Gowns Market report starts from illustration of Industry Chain structure, and portrays industry condition, at that point investigations advertise size and figure of Protective Medical Gowns by item, district and application, likewise, this report presents showcase rivalry circumstance among the merchants profile, plus, advertise value examination and esteem chain highlights are canvassed in this report.Read More: https://www.marketstudyreport.com/reports/global-protective-medical-gowns-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Read More Reports On: https://www.marketwatch.com/press-release/51-growth-for-extracorporeal-shock-wave-lithotripter-market-size-raising-to-usd-470-million-by-2025-2020-03-19?tesla=y

Read More Reports On: https://www.marketwatch.com/press-release/at-38-cagr-hazardous-area-signaling-devices-market-size-set-to-register-2170-million-usd-by-2025-2020-03-23?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the original post:
Unexpected Growth Seen in Stem Cell Characterization and Analysis Tool Market from 2020 to 2025 - Bulletin Line

UCLA

Dr. Amar Kishan

FINDINGS

Researchers at the UCLA Jonsson Comprehensive Cancer Center analyzed gene-expression patterns in the most aggressive prostate cancer grade group known as Gleason grade group 5 and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences. The findings may affect how people are treated for the disease.

One subtype, which accounts for about 15% of the grade group 5 cancers, has highly aggressive features and is associated with much worse outcomes than the other subtypes. Another, which makes up about 20% of the tumors, appears to be much less aggressive and may not require intensified and aggressive treatments. Traditionally, all tumors in Gleason grade group 5 have been treated in the same way.

BACKGROUND

Prostate cancer is the leading solid-tumor cancer among men in the United States and a major cause of morbidity globally. While early-stage, localized prostate cancer is curable, current treatments dont always work for everyone. To find out why standard treatment may work for some and not others, the UCLA researchers looked at tumors in the Gleason grade group 5 subset of prostate cancer. These tumors are at the highest risk to fail standard treatment, leading to metastasis and death. The researchers thought that studying the gene expression the unique signature of each cancer cell in these tumors might provide insight into how to make treatments more personalized for each patient.

METHOD

The researchers first analyzed data from more than 2,100 Gleason grade group 5 tumors, looking at how the genetic blueprints differed among the tumors. They identified distinct clusters of subgroups and validated their findings by analyzing an additional cohort of more than 1,900 Gleason grade group 5 prostate cancers.

IMPACT

By using the genetic information from tumors in men with prostate cancer, physicians hope to one day create more personalized treatments based on the actual characteristics of the cancer. This information will help optimize quality of life and avoid overtreating subgroups of men who may not need aggressive treatments.

AUTHORS

The studys lead author is Dr. Amar Kishan, an assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Jonsson Comprehensive Cancer Center. The co-senior authors are Dr. Joanne Weidhaas, a professor of radiation oncology and director of translational research at the Geffen School of Medicine, and Paul Boutros, a professor of urology and human genetics and director of cancer data science for the Jonsson Cancer Center. Boutros is also a member of the UCLA Institute of Urologic Oncology and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at UCLA. Other UCLA authors include David Elashoff, Dr. Rob Reiter and Dr. Matthew Rettig.

JOURNAL

The study was published in the journal European Urology.

FUNDING

The research was funded in part by an award from the American Society for Radiation Oncology and the Prostate Cancer Foundation, the Radiological Society of North America, and the National Institutes of Health.

Go here to see the original:
Some types of prostate cancer may not be as aggressive as originally thought - Mirage News

Human Mesenchymal Stem Cells (hMSC) Market Sales 2020-2026

Worldwide Human Mesenchymal Stem Cells (hMSC) Market Report 2020-2026 is a systematic and insightful compilation of valuable evaluations of Human Mesenchymal Stem Cells (hMSC) market and relevant aspects. The report offers an in depth exploration of the market and its scope, trends, structure, production, profitability and maturity.

The precise evaluation of market size, share, revenue, sales volume, demand, and rate of growth involved within the report drive investors, industry experts, researchers, also as novice and well-established market players to grasp the general Human Mesenchymal Stem Cells (hMSC) market structure.

Report: calibreresearch.com/report/est-sample The Human Mesenchymal Stem Cells (hMSC) market report also delivers an in-depth analysis of the emerging industry trends along side the restraints, key players, and opportunities within the Human Mesenchymal Stem Cells (hMSC) market to supply worthwhile insights also as a gift scenario for generating right decision.

Moreover, the new report on the Human Mesenchymal Stem Cells (hMSC) industry covers the prominent vendors within the universal market alongside SWOT analysis, fiscal overview and major developments. The world Human Mesenchymal Stem Cells (hMSC) Market report is considered as a detailed investigation of the respective market that will provide key solutions for establishment of profit-driven business strategies.

It is helpful for offering details about futuristic Human Mesenchymal Stem Cells (hMSC) industry trends and in-depth assessment of the international industry. It permits you to determine remarkable challenges and risk factors alongside major opportunities available in the world Human Mesenchymal Stem Cells (hMSC) market.

This report also exhibits the whole historical and current status of the Human Mesenchymal Stem Cells (hMSC) Market worldly. Apart from this, the report on the Human Mesenchymal Stem Cells (hMSC) industry also represents the graphical representation of the upcoming Human Mesenchymal Stem Cells (hMSC) Market infrastructure and the Compound Annual Growth Rate (CAGR) in detail.

Report: calibreresearch.com/report/for-buying

The report on the Human Mesenchymal Stem Cells (hMSC) market is an exclusive and deep study which delivers a comprehensive overview of the industry contains the recent trends and future proportions of the Human Mesenchymal Stem Cells (hMSC) market in terms of product and services. Meanwhile, this report offers a professional research study on the Human Mesenchymal Stem Cells (hMSC) market so as to guage the remarkable vendors by calibrating all the relevant products or services to know the positioning of the key players within the Human Mesenchymal Stem Cells (hMSC) market worldly.

Leading companies reviewed in the Human Mesenchymal Stem Cells (hMSC) report are: PromoCell ThermoFisher KURABO Lifeline Cell Technology Merck The Human Mesenchymal Stem Cells (hMSC) Market report is segmented into following categories: The product segment of the report offers product market information such as demand, supply and market value of the product. The application of product in terms of USD value is represented in numerical and graphical format for all the major regional markets.

The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Type by following categories; Umbilical Cord Matrix hMSC Bone Marrow hMSC Adipose Tissue hMSC Other The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Application by following categories; Medical Application Research Other Applications

Report: calibreresearch.com/report/est-sample

The world Human Mesenchymal Stem Cells (hMSC) marketing research report offers an in depth summary of the foremost desirable factors and informative details about the universal industry. Moreover, the study provides an in-depth summary and forecast of the worldwide Human Mesenchymal Stem Cells (hMSC) market on the idea of several segments.

This report also delivers Human Mesenchymal Stem Cells (hMSC) market size and predicted estimations from the year 2020 to 2026 concerning various topological regions including Europe, North America, the center East and Africa, and South America. The research study on the Human Mesenchymal Stem Cells (hMSC) Market is a valuable source of guidance for world customers as it will rapidly fulfil their requirement and speed up their business growth.

It is an advantageous document for both existing industries manufactures including end-user industries, experts, managers, stakeholders and new entrants. We have designed this world Human Mesenchymal Stem Cells (hMSC) Market report in a deeply understandable format so that anyone can grasp each and every aspect related to the respective industry.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow this link:
Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research - WhaTech Technology and Markets News

When people first started to get sick, the focus was on those organs, he said. But that started to shift as health workers saw first thousands and now millions of patients with COVID-19, including many whose symptoms didnt fit the typical profile of a respiratory disease.

Patients were showing up with blood clots, strokes, brain swelling and, on the more mild end of the spectrum, toe pain.

The authors approached their study like a crime scene investigation, trying to figure out why all these strange symptoms were happening, Li said.

And looking at these tissues, what we found was that the respiratory virus had not only infected the lung, but the virus had also made a beeline for the cells lining blood vessels, he said.

When those endothelial cells are damaged by the virus, it makes the blood more likely to clot, he said.

The studys authors saw from close-up pictures that the virus had moved from the air sacs of the lungs, infecting directly into the blood vessel cells.

The cells were being destroyed from the inside out, unlike when someone has high cholesterol and theyre damaged from the outside. There was emergency blood vessel growth as they divided to get more blood flow, which can lead to clots. The immune system trying to clear the virus can also cause inflammation and clotting.

So this is sort of three strikes that we saw in our study to help explain this clotting, Li said.

The damage was found in vast areas of the lungs at the same time, he added, and not just a few pockets.

Thats not something that we normally see with respiratory virus, and it seems to be unique to COVID-19.

His study also looked at the lungs of people who had died from H1N1, and found they had nine times fewer blood clots in the lungs.

An April paper in The Lancet also showed damage to endothelial cells in several areas of the body including the lungs, heart, kidneys, liver and intestines of COVID-19 patients.

Isaac Bogoch, an infectious diseases specialist at the University of Toronto and University Health Network, said he hasnt seen any COVID toes yet but has seen some vascular symptoms such as blood clots, in patients at Toronto General. Its not uncommon for diseases to have an inflammatory component, he said.

Cat-scratch disease, a bacterial infection caused by cats who turn on their owners, is one example.

But its important to remember that most people dont get a blood clot, he said, adding that within hospitals doctors are still seeing blood clots in some individuals but certainly not most individuals.

Lis research might help explain, though, why older people and those with conditions like diabetes or heart disease tend to have worse outcomes. Their blood vessels are already more vulnerable.

And it does open some new doors of thinking about treatments, Li said.

Blood thinners could be one example. There are also ongoing clinical trials looking at dilating the blood vessels with nitric oxide, and stem cell treatments to regenerate the cells. Its also important to remember that maintaining a nutritious diet can help keep blood vessels healthy, he added.

A New England Journal of Medicine paper from early May looked at outcomes of 8,910 patients across Asia, North America and Europe. It found that the use of either ACE inhibitors (medications that dilate blood vessels) or statins (drugs that help lower cholesterol) was associated with better survival. But the study could not prove a cause-and-effect relationship as it was not a randomized, controlled trial.

Researchers still dont know why COVID-19 is so much worse for some seemingly healthy people than for others, at what point the blood vessel damage starts to occur, and why blood vessels are affected in some parts of the body but not others.

The unknowns of this disease still far outnumber the knowns, so it will take time to construct the full picture of how the SARS- COV2 virus actually causes COVID-19, Li said. But blood clotting could help explain COVID toes, as well as more serious symptoms like strokes.

Multisystem inflammatory syndrome, which has been diagnosed in a small number of kids and teens who test positive for COVID-19 or antibodies that suggest they had it, may also be connected to blood vessel damage, he added.

Luckily, Jake didnt experience any severe issues, but he did have an on-and-off fever. Hes the only one in his family who had the COVID toes. His dad, Jeff, said he had the heavy, heavy chest and didnt feel like he had a full set of lungs but was lucky it didnt get more serious. His younger sister Ella had a low-grade fever for several days, but his mom and two other siblings didnt notice anything out of the ordinary.

They were told by doctors, who diagnosed Jakes toes through virtual visits, to assume they all had it, said Jeff. And their family shows the wide range of effects the disease can have on different people.

Weve got four kids, so we have a larger sample size, he said with a laugh. Weve shared air amongst us and 50 per cent had issues and 50 per cent didnt.

The Reymer family was initially told not to go for testing and just to keep self-isolating. By the time Jake and his father did get tested weeks later, when it opened up to people with more unusual symptoms, they were both negative, possibly because the virus had already cleared from their systems. The province is now urging anyone with even one mild symptom, including loss of taste and smell, and COVID toes, to get a test, as well as asymptomatic people who work in front-line jobs or think they may have been exposed.

Jake is now back to playing basketball and walking around the neighbourhood. Hes feeling good and his toes seem to be improving. But theyre still purple.

They havent shown any real signs of resolving, he said.

Im 100 per cent, its just my toes still arent normal.

May Warren is a Toronto-based breaking news reporter for the Star. Follow her on Twitter: @maywarren11

See the article here:
Is COVID-19 actually a disease of the blood vessels? New research could help explain odd symptoms from strokes to purple toes - The Flamborough Review